UY34916A - "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC " - Google Patents

"SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC "

Info

Publication number
UY34916A
UY34916A UY0001034916A UY34916A UY34916A UY 34916 A UY34916 A UY 34916A UY 0001034916 A UY0001034916 A UY 0001034916A UY 34916 A UY34916 A UY 34916A UY 34916 A UY34916 A UY 34916A
Authority
UY
Uruguay
Prior art keywords
solid preparation
metilsulfonil
bifenil
propoxi
dimetil
Prior art date
Application number
UY0001034916A
Other languages
Spanish (es)
Inventor
Hoshina Wataru
Mima Yasushi
Hohokabe Miyuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34916A publication Critical patent/UY34916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una preparación sólida superior en la propiedad de desintegración y estabilidad de preservación. La presente invención se refiere a una preparación sólida que contiene (1) el compuesto (A) o una de sus sales, (2) metformina o una de sus sales y (3) crospovidona. También se refiere a un compuesto (A) o una de sus sales superiores en la propiedad de disolución.The present invention provides a superior solid preparation in the property of decay and preservation stability. The present invention relates to a solid preparation containing (1) the compound (A) or a salt thereof, (2) metformin or a salt thereof and (3) crospovidone. It also refers to a compound (A) or one of its higher salts in the dissolution property.

UY0001034916A 2012-07-19 2013-07-17 "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC " UY34916A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012161025A JP2015127299A (en) 2012-07-19 2012-07-19 Solid preparation

Publications (1)

Publication Number Publication Date
UY34916A true UY34916A (en) 2014-02-28

Family

ID=48980240

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034916A UY34916A (en) 2012-07-19 2013-07-17 "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC "

Country Status (5)

Country Link
JP (1) JP2015127299A (en)
AR (1) AR092351A1 (en)
TW (1) TW201408290A (en)
UY (1) UY34916A (en)
WO (1) WO2014014129A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210640A1 (en) 2018-02-13 2021-03-23 Gilead Sciences Inc INHIBITORS PD-1 / PD-L1
TWI712412B (en) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd-1/pd-l1 inhibitors
ES2962674T3 (en) 2018-07-13 2024-03-20 Gilead Sciences Inc PD-1/PD-L1 inhibitors
CN112955435B (en) 2018-10-24 2024-09-06 吉利德科学公司 PD-1/PD-L1 inhibitors
JP2021104941A (en) * 2019-12-26 2021-07-26 ニプロ株式会社 Tablets with high drug content and manufacturing methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
ZA200503967B (en) 2002-11-01 2006-11-29 Takeda Pharmaceutical Agent for preventing or treating neuropathy
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical Thiazoline derivative and use of the same
WO2005058823A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical Phenoxyalkanoic acid compound
PE20070338A1 (en) 2005-08-10 2007-04-16 Takeda Pharmaceutical HETEROCYCLIC DERIVATIVES AS THERAPEUTIC AGENTS FOR DIABETES
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
UA95296C2 (en) 2006-06-27 2011-07-25 Такеда Фармасьютікал Компані Лімітед Fused cyclic compounds
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical Fused heterocyclic compound
GEP20115241B (en) 2006-10-19 2011-06-10 Takeda Pharmaceutical Indole compound
WO2008093639A1 (en) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited Pyrazole compound
BRPI0807014A2 (en) 2007-02-09 2014-04-22 Takeda Pharmaceutical COMPOUND, PRODUCT, PHARMACEUTICAL AGENT, METHODS FOR IMPROVING INSULIN RESISTANCE IN A MAMMER, METHOD FOR PROPHYLAXY OR TREATMENT IN A MAMMAL, AND USE OF A COMPOUND.
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
JP2012161025A (en) 2011-02-02 2012-08-23 Mitsubishi Electric Corp Cable diagnostic device and cable diagnostic method

Also Published As

Publication number Publication date
AR092351A1 (en) 2015-04-15
JP2015127299A (en) 2015-07-09
TW201408290A (en) 2014-03-01
WO2014014129A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
CL2016002970A1 (en) Addition salts of (s) -2- (1- (6-amino-5-cyanopyrimidin-4-ylamino) ethyl) -4-oxo-3-phenyl-3,4-dihydropyrrolo [1,2-f] [ 1,2,4] triazine-5-carbonitrile.
EA201300200A1 (en) N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
RS54873B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CO6511251A2 (en) CHEMICAL COMPOUNDS
CY1123456T1 (en) METHOD OF PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROME-4-ONE DERIVATIVES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
CO6420351A2 (en) PESTICIDED COMPOSITIONS
ECSP12012208A (en) ORAL FORMULATIONS AND LIPOPHYLIC SALTS OF METHYLNTREXONE
CO6331463A2 (en) NEW DERIVATIVES OF TRIAZOLO (4,3-A) PIRIDINA, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE IN PARTICULARLY AS MET INHIBITORS
UY34916A (en) "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC "
CO6741154A2 (en) Triazolopyridine Compounds
UY32126A (en) SOLID PHARMACEUTICAL COMPOSITION
CL2013003563A1 (en) Compounds derived from gambogic acid amides and their salts; pharmaceutical composition comprising them, useful in the treatment of glioblastoma.
NI201100149A (en) DERIVATIVES OF TIADIAZOLES AND OXADIAZOLES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY.
CR20140053A (en) DEOXICOLIC ACID FORMULATIONS AND SALTS OF THE SAME
AR089486A1 (en) PHARMACEUTICAL PREPARATION INCLUDING b-CYCLODEXTRINE REPLACED
NI201100051A (en) SALTS OF N - [6 - (CIS - 2,6 - DIMETHYL - MORPHOLIN - 4 - IL) - PYRIDIN - 3 - IL] - 2 - METHYL - 4 '- (TRIFLUORO - METOXI) - [1, 1' - BIPHENYL ] - 3 - CARBOXAMIDE.
ES2585558T3 (en) Use of 3-carboxy-N-ethyl-N, N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UY32333A (en) QUATERNARY DERIVATIVES OF PIRIDINE AND USE OF THE SAME
ES2513569T3 (en) Prolonged release formulation comprising a metastin derivative
TH129179A (en)
TH173507A (en) Welded-loop derivatives of dihydropyrimidoes as HBV inhibitors
TH158502A (en) Heterocyclic compounds
TH156221A (en) 4- (8-methoxy-1 - ((1-methoxipropane-2-il) -2- (tetrahydro-2H-pyran-4-il) - 1H-imidaiso [4.5-C] -quinolin-7-il) -3,5-dimethyl isosazole And their use as a bromodomain inhibitor.
TH168863A (en) Pirasol-amide compounds And its medical use
TH105092A (en) Benzoquinasoline derivatives

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140715